Compare
Tarsus Pharmaceuticals, Inc. vs ADMA Biologics, Inc. vs Repligen Corp vs Adaptimmune Therapeutics PLC
| Latest fiscal year | Tarsus Pharmaceuticals, Inc. TARS | ADMA Biologics, Inc. ADMA | Repligen Corp RGEN | Adaptimmune Therapeutics PLC ADAPYLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2024-12-31 |
| Revenue | $451.36M | $510.17M | $738.26M | $178.03M |
| Revenue growth (YoY) | +146.7% | +19.6% | +16.4% | +195.3% |
| Gross margin | n/a | 57.4% | 52.3% (computed) | n/a |
| Operating margin | -15.7% | 37.5% | 7.5% | -38.6% |
| Net margin | -14.7% | 28.8% | 6.6% | -39.8% |
| Net income | -$66.42M | $146.93M | $48.89M | -$70.81M |
| EPS (Diluted) | -$1.59 | $0.60 | $0.86 | -$0.05 |
| Operating cash flow | -$12.45M | $50.40M | $117.42M | -$73.21M |
| Free cash flow | -$22.31M | $27.82M | $93.90M | -$74.09M |
| Cash & equivalents | $183.64M | $87.63M | $566.02M | $91.14M |
| Total assets | $562.16M | $624.24M | $2.95B | $245.96M |
| Total liabilities | $218.73M | $146.92M | $843.57M | $234.11M |
| Shareholders' equity | $343.43M | $477.32M | $2.11B | $11.85M |
| Return on year-end equity | -19.3% | 30.8% | 2.3% | -597.6% |
| Shares outstanding | 42.55M | 237.87M | 56.33M | 1.54B |
Revenue, most recent five fiscal years
| Fiscal year | Tarsus Pharmaceuticals, Inc. | ADMA Biologics, Inc. | Repligen Corp | Adaptimmune Therapeutics PLC |
|---|---|---|---|---|
| Latest | $451.36M Ended 2025-12-31 | $510.17M Ended 2025-12-31 | $738.26M Ended 2025-12-31 | $178.03M Ended 2024-12-31 |
| 1 year earlier | $182.95M Ended 2024-12-31 | $426.45M Ended 2024-12-31 | $634.44M Ended 2024-12-31 | $60.28M Ended 2023-12-31 |
| 2 years earlier | $17.45M Ended 2023-12-31 | $258.21M Ended 2023-12-31 | $632.36M Ended 2023-12-31 | $27.15M Ended 2022-12-31 |
| 3 years earlier | $25.82M Ended 2022-12-31 | $154.08M Ended 2022-12-31 | $801.54M Ended 2022-12-31 | $6.15M Ended 2021-12-31 |
| 4 years earlier | $57.03M Ended 2021-12-31 | $80.94M Ended 2021-12-31 | $670.53M Ended 2021-12-31 | $3.96M Ended 2020-12-31 |